1-Methylpyrazole-4-boronic acid pinacol ester

• Catalog No.: 595314
• CAS Number: 761446-44-0
• M. F.: C10H17BN2O2
• M. W.: 208.06518
• Purity: 95%

SYNONYMS

• Title: 1-甲基吡唑-4-硼酸频哪醇酯
• IUPAC name: 1-methyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
• IUPAC Traditional name: 1-methyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole
• Synonyms: 1-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole; 1-甲基-4-吡唑硼酸频哪醇酯; 1-Methyl-4-pyrazoleboronic acid pinacol ester; 1-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole; 2-(1-Methylpyrazol-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1-methylpyrazole; 1-甲基-4-(4,4,5,5-四甲基-1,3,2-二氧杂戊硼烷-2-基)-1H-吡唑

DATABASE IDS

• CAS Number: 761446-44-0
• PubChem SID: 24881568
• MDL Number: MFCD03789259

PROPERTIES

• Empirical Formula (Hill Notation): C10H17BN2O2
• Purity: 95%
• Melting Point: 59-64 °C(lit.)
• GHS Signal Word: Warning
• GHS Hazard statements: H302-H315-H319-H335
• European Hazard Symbols: Harmful (Xn)
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Faceshields, Gloves
• GHS Precautionary statements: P261-P305 + P351 + P338
• Risk Statements: 22-36/37/38
• Safety Statements: 26-36
• German water hazard class: 3

DETAILS

Description (English)

Packaging
1, 5, 25 g in glass bottle
Application
Reagent used for
• Suzuki-Miyaura cross-coupling reactions1,2,3
• Transesterification reactions4Reagent used for preparation of
• Aminothiazoles as γ-secretase modulators5
• Amino-pyrido-indol-carboxamides, as potential JAK2 inhibitors for myeloproliferative disorders therapy6
• Pyridine derivatives as TGF-β1 and activin A signalling inhibitors7
• MK-2461 analogs as inhibitors of c-Met kinase for the treatment of cancer8

Description (简体中文)

包装
1, 5, 25 g in glass bottle
Application
Reagent used for
• Suzuki-Miyaura cross-coupling reactions1,2,3
• Transesterification reactions4Reagent used for preparation of
• Aminothiazoles as γ-secretase modulators5
• Amino-pyrido-indol-carboxamides, as potential JAK2 inhibitors for myeloproliferative disorders therapy6
• Pyridine derivatives as TGF-β1 and activin A signalling inhibitors7
• MK-2461 analogs as inhibitors of c-Met kinase for the treatment of cancer8